Discussions with FDA: Design of CAM211 Pivotal Study

• Based upon 125-005 and 125-009 data

• Single-arm, multicenter study

• Strictly defined fludarabine failure

• Primary endpoint: response rate

• 30 mg 3x/week

CAM211 Study Design

Previous slide

Next slide

Back to first slide

View graphic version